Beijing Sun Novo Pharmaceutical Research Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 2.04%

Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has an Asset Resilience Ratio of 2.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beijing Sun Novo Pharmaceutical Research financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥47.00 Million

≈ $6.88 Million USD Cash + Short-term Investments

Total Assets

CN¥2.30 Billion

≈ $336.59 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Asset Resilience Ratio has changed over time. See 688621 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Beijing Sun Novo Pharmaceutical Research Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Beijing Sun Novo Pharmaceutical Research worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥47.00 Million	2.04%
Total Liquid Assets	CN¥47.00 Million	2.04%

Asset Resilience Insights

Limited Liquidity: Beijing Sun Novo Pharmaceutical Research Co Ltd maintains only 2.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Beijing Sun Novo Pharmaceutical Research Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Sun Novo Pharmaceutical Research Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	0.76%
Eris Lifesciences Limited NSE:ERIS	Drug Manufacturers - Specialty & Generic	0.58%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.01%
Lotus Pharmaceutical Co Ltd TW:1795	Drug Manufacturers - Specialty & Generic	0.49%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	11.69%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	18.70%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Sun Pharma Advanced Research Company Limited NSE:SPARC	Drug Manufacturers - Specialty & Generic	0.64%

Annual Asset Resilience Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Sun Novo Pharmaceutical Research Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	3.28%	CN¥75.00 Million ≈ $10.97 Million	CN¥2.28 Billion ≈ $334.34 Million	+1.77pp
2024-12-31	1.51%	CN¥30.00 Million ≈ $4.39 Million	CN¥1.99 Billion ≈ $290.81 Million	-0.10pp
2023-12-31	1.61%	CN¥30.00 Million ≈ $4.39 Million	CN¥1.86 Billion ≈ $272.62 Million	+0.71pp
2022-12-31	0.90%	CN¥13.11 Million ≈ $1.92 Million	CN¥1.46 Billion ≈ $214.10 Million	-11.79pp
2021-12-31	12.68%	CN¥157.60 Million ≈ $23.06 Million	CN¥1.24 Billion ≈ $181.84 Million	--

pp = percentage points

About Beijing Sun Novo Pharmaceutical Research Co Ltd

SHG:688621 China Drug Manufacturers - Specialty & Generic

Market Cap

$858.79 Million

CN¥5.87 Billion CNY

Market Cap Rank

#9735 Global

#2581 in China

Share Price

CN¥52.40

Change (1 day)

+1.99%

52-Week Range

CN¥45.94 - CN¥82.41

All Time High

CN¥128.22